Lv37
220 积分 2024-03-11 加入
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
2天前
已完结
Important Pathologic Considerations for Establishing the Diagnosis of Myelofibrosis
3天前
求助中
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
10天前
已完结
Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer
11天前
已完结
Implementation of Bispecific Antibodies in the Community: Lessons From the ThedaCare Cancer Center Experience
19天前
已完结
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries
1个月前
已完结
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry
1个月前
已完结
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
1个月前
已完结
How I treat anemia in myelofibrosis
1个月前
已完结
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study
1个月前
已完结
皖公网安备34019202002308
